Comparing drug safety of hepatitis C therapies using post-market data

Comparing drug safety of hepatitis C therapies using post-market data

Abstract Background Hepatitis C affects about 3 % of the world’s population. In the United States, about 3.5 million have chronic hepatitis C, and it is the leading cause of liver cancer and the most common indication for liver transplantation. In the last decades, new advances in therapy have subst...

Full description

Bibliographic Details
Main Authors: Jing Huang, Xinyuan Zhang, Jiayi Tong, Jingcheng Du, Rui Duan, Liu Yang, Jason H. Moore, Cui Tao, Yong Chen
Format: Article
Language:English
Published: BMC 2019-08-01
Series:BMC Medical Informatics and Decision Making
Subjects:
Adverse drug reaction reporting systems
Electronic medical record
Data mining
Hepatitis C
Regulatory decision support
Online Access:http://link.springer.com/article/10.1186/s12911-019-0860-6

Internet

http://link.springer.com/article/10.1186/s12911-019-0860-6

Similar Items